[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fyvMb8qmi8CP0Qf0o9S4JbK83FOzAXKbtUJCbKZFZpRY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":80,"rows":87},"Wayne State University",[4],224,false,38,6,26685,15,162,[14,17,20,22,24,26,28,31],{"name":15,"count":16},"Hypertension",10,{"name":18,"count":19},"Heroin Dependence",7,{"name":21,"count":9},"Multiple Sclerosis",{"name":23,"count":9},"Post Traumatic Stress Disorder",{"name":25,"count":9},"Opioid-Related Disorders",{"name":27,"count":9},"Marijuana Abuse",{"name":29,"count":30},"Type 1 Diabetes",5,{"name":32,"count":33},"PTSD",4,[35,40,45,50,55,60,65,70,75],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT06297499","Ondansetron Use for Preventing Pruritus in Patients Undergoing Cesarean Section","2025-08-01","Ondansetron 8mg",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT04066348","TNF-α Treatment of Blast-Induced Tinnitus","2026-09","Etanercept",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05006079","Opioid\u002FBenzodiazepine Polydrug Abuse: Aim 3","2026-12","Morphine",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT07123467","Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder","2027-08-31","Low-Dose Cannabidiol",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT04231708","Effects of Pharmacological Stress and rTMS on Executive Function in Opioid Use Disorder","2028-12","Yohimbine + Hydrocortisone",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT05022459","Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis","2029-01","Emicizumab",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT07222306","Cannabis, Neuroinflammation, and Suicidal Ideation: A Supplemental Brain Imaging Study","2030-08-31","1-(2-[+F]fluoroethyl)-L-tryptophan",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT06381180","Warrior CARE: Cannabis Behavioral Health","2030-12-31","Tetrahydrocannabinol",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT06222268","Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery","2031-09","Cannabidiol (CBD) only",[81,82,83,84,85,86],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[88,114,132,173,197,215,236,261,289,311,329,347,369,393,416,434,460,485,510,536,554,580,598,623,646,673,691,717,743,761,787,812,837,862,888,906,932,950,975,993,1019,1044,1069,1087,1112,1137,1163,1181,1210,1228,1246,1264,1282,1306,1331,1356,1383,1401,1419,1442,1467,1490,1515,1538,1562,1588,1606,1632,1670,1688,1706,1731,1749,1775,1798,1827,1852,1876,1894,1918,1942,1968,1986,2004,2022,2050,2075],{"intervention":54,"totalTrials":89,"cells":90},1,{"EARLY_PHASE1":91,"PHASE1":94,"PHASE2":96,"PHASE3":98,"PHASE4":110,"NA":112},{"trials":92,"activeCount":93},[],0,{"trials":95,"activeCount":93},[],{"trials":97,"activeCount":93},[],{"trials":99,"activeCount":89,"soonestReadout":53},[100],{"nctId":51,"briefTitle":52,"status":101,"phases":102,"primaryCompletion":53,"completion":53,"start":103,"enrollment":104,"conditions":105,"interventions":108},"RECRUITING",[84],"2025-11-03",90,[106,107],"Generalized Anxiety Disorder (GAD)","Anxiety Disorders",[54,109],"Moderate-Dose Cannabidiol",{"trials":111,"activeCount":93},[],{"trials":113,"activeCount":93},[],{"intervention":109,"totalTrials":89,"cells":115},{"EARLY_PHASE1":116,"PHASE1":118,"PHASE2":120,"PHASE3":122,"PHASE4":128,"NA":130},{"trials":117,"activeCount":93},[],{"trials":119,"activeCount":93},[],{"trials":121,"activeCount":93},[],{"trials":123,"activeCount":89,"soonestReadout":53},[124],{"nctId":51,"briefTitle":52,"status":101,"phases":125,"primaryCompletion":53,"completion":53,"start":103,"enrollment":104,"conditions":126,"interventions":127},[84],[106,107],[54,109],{"trials":129,"activeCount":93},[],{"trials":131,"activeCount":93},[],{"intervention":59,"totalTrials":133,"cells":134},3,{"EARLY_PHASE1":135,"PHASE1":137,"PHASE2":139,"PHASE3":167,"PHASE4":169,"NA":171},{"trials":136,"activeCount":93},[],{"trials":138,"activeCount":93},[],{"trials":140,"activeCount":89,"soonestReadout":58},[141,151,159],{"nctId":142,"briefTitle":143,"status":144,"phases":145,"primaryCompletion":146,"completion":146,"start":146,"enrollment":93,"conditions":147,"interventions":150},"NCT04181515","Using rTMS to Explore Neural Mechanisms of Stress-Induced Opioid Use","WITHDRAWN",[83],"2023-04-10",[148,149],"Stress","Opioid-use Disorder",[59],{"nctId":56,"briefTitle":57,"status":152,"phases":153,"primaryCompletion":58,"completion":58,"start":154,"enrollment":155,"conditions":156,"interventions":158},"NOT_YET_RECRUITING",[83],"2026-10",20,[157],"Opioid Use Disorder",[59],{"nctId":160,"briefTitle":161,"status":144,"phases":162,"primaryCompletion":146,"completion":146,"start":146,"enrollment":93,"conditions":163,"interventions":165},"NCT04180969","rTMS of Limbic Circuitry in Stress Modulation in Healthy Volunteers",[83],[148,164],"Healthy",[166],"yohimbine + hydrocortisone",{"trials":168,"activeCount":93},[],{"trials":170,"activeCount":93},[],{"trials":172,"activeCount":93},[],{"intervention":49,"totalTrials":89,"cells":174},{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":179,"PHASE3":191,"PHASE4":193,"NA":195},{"trials":176,"activeCount":93},[],{"trials":178,"activeCount":93},[],{"trials":180,"activeCount":89,"soonestReadout":48},[181],{"nctId":46,"briefTitle":47,"status":101,"phases":182,"primaryCompletion":48,"completion":48,"start":183,"enrollment":184,"conditions":185,"interventions":189},[83],"2024-03-13",24,[186,187,188],"Opioid Abuse","Benzodiazepine Abuse","Polysubstance Abuse",[49,190],"Alprazolam",{"trials":192,"activeCount":93},[],{"trials":194,"activeCount":93},[],{"trials":196,"activeCount":93},[],{"intervention":190,"totalTrials":89,"cells":198},{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":209,"PHASE4":211,"NA":213},{"trials":200,"activeCount":93},[],{"trials":202,"activeCount":93},[],{"trials":204,"activeCount":89,"soonestReadout":48},[205],{"nctId":46,"briefTitle":47,"status":101,"phases":206,"primaryCompletion":48,"completion":48,"start":183,"enrollment":184,"conditions":207,"interventions":208},[83],[186,187,188],[49,190],{"trials":210,"activeCount":93},[],{"trials":212,"activeCount":93},[],{"trials":214,"activeCount":93},[],{"intervention":44,"totalTrials":89,"cells":216},{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":221,"PHASE3":230,"PHASE4":232,"NA":234},{"trials":218,"activeCount":93},[],{"trials":220,"activeCount":93},[],{"trials":222,"activeCount":89,"soonestReadout":43},[223],{"nctId":41,"briefTitle":42,"status":101,"phases":224,"primaryCompletion":43,"completion":43,"start":225,"enrollment":226,"conditions":227,"interventions":229},[83],"2022-07-01",88,[228],"Tinnitus, Noise Induced",[44],{"trials":231,"activeCount":93},[],{"trials":233,"activeCount":93},[],{"trials":235,"activeCount":93},[],{"intervention":237,"totalTrials":89,"cells":238},"Cannabidiol",{"EARLY_PHASE1":239,"PHASE1":241,"PHASE2":243,"PHASE3":255,"PHASE4":257,"NA":259},{"trials":240,"activeCount":93},[],{"trials":242,"activeCount":93},[],{"trials":244,"activeCount":89,"soonestReadout":73},[245],{"nctId":71,"briefTitle":72,"status":152,"phases":246,"primaryCompletion":73,"completion":73,"start":247,"enrollment":248,"conditions":249,"interventions":254},[82,83],"2025-09-22",500,[23,250,251,252,253],"Cannabis Use","Suicide","Veterans","Marijuana",[74,237],{"trials":256,"activeCount":93},[],{"trials":258,"activeCount":93},[],{"trials":260,"activeCount":93},[],{"intervention":74,"totalTrials":262,"cells":263},2,{"EARLY_PHASE1":264,"PHASE1":266,"PHASE2":268,"PHASE3":274,"PHASE4":276,"NA":278},{"trials":265,"activeCount":93},[],{"trials":267,"activeCount":93},[],{"trials":269,"activeCount":89,"soonestReadout":73},[270],{"nctId":71,"briefTitle":72,"status":152,"phases":271,"primaryCompletion":73,"completion":73,"start":247,"enrollment":248,"conditions":272,"interventions":273},[82,83],[23,250,251,252,253],[74,237],{"trials":275,"activeCount":93},[],{"trials":277,"activeCount":93},[],{"trials":279,"activeCount":93},[280],{"nctId":281,"briefTitle":282,"status":283,"phases":284,"completion":285,"start":286,"enrollment":155,"conditions":287,"interventions":288},"NCT00218504","Responses to Marijuana-Related Cues Versus Neutral Cues in Adults Taking Tetrahydrocannabinol (THC) - 2","COMPLETED",[],"2009-10","2005-12",[27],[74],{"intervention":79,"totalTrials":89,"cells":290},{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":303,"PHASE3":305,"PHASE4":307,"NA":309},{"trials":292,"activeCount":93},[],{"trials":294,"activeCount":89,"soonestReadout":78},[295],{"nctId":76,"briefTitle":77,"status":152,"phases":296,"primaryCompletion":78,"completion":78,"start":297,"enrollment":298,"conditions":299,"interventions":300},[82],"2026-03",280,[32,23],[79,301,302],"Delta-9-tetrahydrocannabinol (THC) only","THC:CBD 1:1",{"trials":304,"activeCount":93},[],{"trials":306,"activeCount":93},[],{"trials":308,"activeCount":93},[],{"trials":310,"activeCount":93},[],{"intervention":301,"totalTrials":89,"cells":312},{"EARLY_PHASE1":313,"PHASE1":315,"PHASE2":321,"PHASE3":323,"PHASE4":325,"NA":327},{"trials":314,"activeCount":93},[],{"trials":316,"activeCount":89,"soonestReadout":78},[317],{"nctId":76,"briefTitle":77,"status":152,"phases":318,"primaryCompletion":78,"completion":78,"start":297,"enrollment":298,"conditions":319,"interventions":320},[82],[32,23],[79,301,302],{"trials":322,"activeCount":93},[],{"trials":324,"activeCount":93},[],{"trials":326,"activeCount":93},[],{"trials":328,"activeCount":93},[],{"intervention":302,"totalTrials":89,"cells":330},{"EARLY_PHASE1":331,"PHASE1":333,"PHASE2":339,"PHASE3":341,"PHASE4":343,"NA":345},{"trials":332,"activeCount":93},[],{"trials":334,"activeCount":89,"soonestReadout":78},[335],{"nctId":76,"briefTitle":77,"status":152,"phases":336,"primaryCompletion":78,"completion":78,"start":297,"enrollment":298,"conditions":337,"interventions":338},[82],[32,23],[79,301,302],{"trials":340,"activeCount":93},[],{"trials":342,"activeCount":93},[],{"trials":344,"activeCount":93},[],{"trials":346,"activeCount":93},[],{"intervention":39,"totalTrials":89,"cells":348},{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":361,"PHASE3":363,"PHASE4":365,"NA":367},{"trials":350,"activeCount":93},[],{"trials":352,"activeCount":89,"soonestReadout":38},[353],{"nctId":36,"briefTitle":37,"status":101,"phases":354,"primaryCompletion":38,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":360},[82],"2025-12-01","2024-08-22",66,[359],"Pruritus Caused by Drug",[39],{"trials":362,"activeCount":93},[],{"trials":364,"activeCount":93},[],{"trials":366,"activeCount":93},[],{"trials":368,"activeCount":93},[],{"intervention":69,"totalTrials":89,"cells":370},{"EARLY_PHASE1":371,"PHASE1":373,"PHASE2":375,"PHASE3":377,"PHASE4":379,"NA":381},{"trials":372,"activeCount":93},[],{"trials":374,"activeCount":93},[],{"trials":376,"activeCount":93},[],{"trials":378,"activeCount":93},[],{"trials":380,"activeCount":93},[],{"trials":382,"activeCount":89,"soonestReadout":68},[383],{"nctId":66,"briefTitle":67,"status":384,"phases":385,"primaryCompletion":68,"completion":68,"start":386,"enrollment":387,"conditions":388,"interventions":392},"ENROLLING_BY_INVITATION",[],"2025-11-01",100,[32,389,390,391],"Suicidal Thoughts and Behaviors","PTSD Symptoms","Depressive Symptoms",[69],{"intervention":64,"totalTrials":89,"cells":394},{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":401,"PHASE4":403,"NA":405},{"trials":396,"activeCount":93},[],{"trials":398,"activeCount":93},[],{"trials":400,"activeCount":93},[],{"trials":402,"activeCount":93},[],{"trials":404,"activeCount":93},[],{"trials":406,"activeCount":89,"soonestReadout":63},[407],{"nctId":61,"briefTitle":62,"status":101,"phases":408,"primaryCompletion":63,"completion":409,"start":410,"enrollment":411,"conditions":412,"interventions":414},[],"2029-03","2023-08-16",72,[413],"Hemophilia A",[64,415],"FVIII",{"intervention":415,"totalTrials":89,"cells":417},{"EARLY_PHASE1":418,"PHASE1":420,"PHASE2":422,"PHASE3":424,"PHASE4":426,"NA":428},{"trials":419,"activeCount":93},[],{"trials":421,"activeCount":93},[],{"trials":423,"activeCount":93},[],{"trials":425,"activeCount":93},[],{"trials":427,"activeCount":93},[],{"trials":429,"activeCount":89,"soonestReadout":63},[430],{"nctId":61,"briefTitle":62,"status":101,"phases":431,"primaryCompletion":63,"completion":409,"start":410,"enrollment":411,"conditions":432,"interventions":433},[],[413],[64,415],{"intervention":435,"totalTrials":89,"cells":436},"Corticosteroids",{"EARLY_PHASE1":437,"PHASE1":439,"PHASE2":441,"PHASE3":443,"PHASE4":445,"NA":458},{"trials":438,"activeCount":93},[],{"trials":440,"activeCount":93},[],{"trials":442,"activeCount":93},[],{"trials":444,"activeCount":93},[],{"trials":446,"activeCount":93},[447],{"nctId":448,"briefTitle":449,"status":450,"phases":451,"primaryCompletion":452,"completion":452,"start":453,"enrollment":454,"conditions":455,"interventions":457},"NCT03878914","Steroid Sensitive Nephrotic Syndrome in Children","TERMINATED",[85],"2021-10-31","2019-08-06",34,[456],"Nephrotic Syndrome in Children",[435],{"trials":459,"activeCount":93},[],{"intervention":461,"totalTrials":89,"cells":462},"Lithium Carbonate",{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":469,"PHASE4":471,"NA":483},{"trials":464,"activeCount":93},[],{"trials":466,"activeCount":93},[],{"trials":468,"activeCount":93},[],{"trials":470,"activeCount":93},[],{"trials":472,"activeCount":93},[473],{"nctId":474,"briefTitle":475,"status":283,"phases":476,"primaryCompletion":477,"completion":477,"start":478,"enrollment":479,"conditions":480,"interventions":482},"NCT00870311","Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients",[85],"2004-04","1996-03",28,[481],"Bipolar Disorder",[461],{"trials":484,"activeCount":93},[],{"intervention":486,"totalTrials":89,"cells":487},"Rosuvastatin",{"EARLY_PHASE1":488,"PHASE1":490,"PHASE2":492,"PHASE3":494,"PHASE4":496,"NA":508},{"trials":489,"activeCount":93},[],{"trials":491,"activeCount":93},[],{"trials":493,"activeCount":93},[],{"trials":495,"activeCount":93},[],{"trials":497,"activeCount":93},[498],{"nctId":499,"briefTitle":500,"status":450,"phases":501,"primaryCompletion":502,"completion":502,"start":503,"enrollment":155,"conditions":504,"interventions":507},"NCT01975194","Rosuvastatin in African Americans With Cerebrovascular Disease",[85],"2013-08","2012-01",[505,506],"Stroke","Transient Ischemic Attack",[486],{"trials":509,"activeCount":93},[],{"intervention":511,"totalTrials":89,"cells":512},"Norethindrone",{"EARLY_PHASE1":513,"PHASE1":515,"PHASE2":517,"PHASE3":519,"PHASE4":521,"NA":534},{"trials":514,"activeCount":93},[],{"trials":516,"activeCount":93},[],{"trials":518,"activeCount":93},[],{"trials":520,"activeCount":93},[],{"trials":522,"activeCount":93},[523],{"nctId":524,"briefTitle":525,"status":283,"phases":526,"primaryCompletion":527,"completion":527,"start":528,"enrollment":529,"conditions":530,"interventions":532},"NCT03594604","Norethindrone for the Delay of Menstruation",[85],"2007-12-15","2007-06-15",17,[531],"Menstrual Flow Altered",[511,533],"oral contraceptive pill",{"trials":535,"activeCount":93},[],{"intervention":533,"totalTrials":89,"cells":537},{"EARLY_PHASE1":538,"PHASE1":540,"PHASE2":542,"PHASE3":544,"PHASE4":546,"NA":552},{"trials":539,"activeCount":93},[],{"trials":541,"activeCount":93},[],{"trials":543,"activeCount":93},[],{"trials":545,"activeCount":93},[],{"trials":547,"activeCount":93},[548],{"nctId":524,"briefTitle":525,"status":283,"phases":549,"primaryCompletion":527,"completion":527,"start":528,"enrollment":529,"conditions":550,"interventions":551},[85],[531],[511,533],{"trials":553,"activeCount":93},[],{"intervention":555,"totalTrials":89,"cells":556},"Cantharidin",{"EARLY_PHASE1":557,"PHASE1":559,"PHASE2":561,"PHASE3":563,"PHASE4":565,"NA":578},{"trials":558,"activeCount":93},[],{"trials":560,"activeCount":93},[],{"trials":562,"activeCount":93},[],{"trials":564,"activeCount":93},[],{"trials":566,"activeCount":93},[567],{"nctId":568,"briefTitle":569,"status":283,"phases":570,"primaryCompletion":528,"completion":571,"start":572,"enrollment":573,"conditions":574,"interventions":576},"NCT03625960","Cantharone for the Treatment of Perenial Warts",[85],"2007-07-15","2006-06-15",12,[575],"Wart, Genital",[555,577],"Trichloroacetic Acid",{"trials":579,"activeCount":93},[],{"intervention":577,"totalTrials":89,"cells":581},{"EARLY_PHASE1":582,"PHASE1":584,"PHASE2":586,"PHASE3":588,"PHASE4":590,"NA":596},{"trials":583,"activeCount":93},[],{"trials":585,"activeCount":93},[],{"trials":587,"activeCount":93},[],{"trials":589,"activeCount":93},[],{"trials":591,"activeCount":93},[592],{"nctId":568,"briefTitle":569,"status":283,"phases":593,"primaryCompletion":528,"completion":571,"start":572,"enrollment":573,"conditions":594,"interventions":595},[85],[575],[555,577],{"trials":597,"activeCount":93},[],{"intervention":599,"totalTrials":89,"cells":600},"Zolpidem",{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":607,"PHASE4":609,"NA":621},{"trials":602,"activeCount":93},[],{"trials":604,"activeCount":93},[],{"trials":606,"activeCount":93},[],{"trials":608,"activeCount":93},[],{"trials":610,"activeCount":93},[611],{"nctId":612,"briefTitle":613,"status":283,"phases":614,"primaryCompletion":615,"completion":615,"start":616,"enrollment":617,"conditions":618,"interventions":620},"NCT04720547","Sleep and Breathing in the General Population - Chemical Stimuli",[85],"2020-02-29","2018-07-03",14,[619],"Sleep-disordered Breathing",[599],{"trials":622,"activeCount":93},[],{"intervention":624,"totalTrials":89,"cells":625},"Perampanel",{"EARLY_PHASE1":626,"PHASE1":628,"PHASE2":630,"PHASE3":632,"PHASE4":634,"NA":644},{"trials":627,"activeCount":93},[],{"trials":629,"activeCount":93},[],{"trials":631,"activeCount":93},[],{"trials":633,"activeCount":93},[],{"trials":635,"activeCount":93},[636],{"nctId":637,"briefTitle":638,"status":450,"phases":639,"primaryCompletion":640,"completion":640,"start":640,"enrollment":89,"conditions":641,"interventions":643},"NCT05684978","Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus",[85],"2025-10-10",[642],"Refractory Status Epilepticus",[624],{"trials":645,"activeCount":93},[],{"intervention":647,"totalTrials":89,"cells":648},"Ceftaroline",{"EARLY_PHASE1":649,"PHASE1":651,"PHASE2":653,"PHASE3":655,"PHASE4":657,"NA":671},{"trials":650,"activeCount":93},[],{"trials":652,"activeCount":93},[],{"trials":654,"activeCount":93},[],{"trials":656,"activeCount":93},[],{"trials":658,"activeCount":93},[659],{"nctId":660,"briefTitle":661,"status":283,"phases":662,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":666,"interventions":669},"NCT02582203","Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA",[85],"2016-05","2012-02",174,[667,668],"Skin Diseases, Infectious","Staphylococcal Skin Infections",[647,670],"Vancomycin",{"trials":672,"activeCount":93},[],{"intervention":670,"totalTrials":89,"cells":674},{"EARLY_PHASE1":675,"PHASE1":677,"PHASE2":679,"PHASE3":681,"PHASE4":683,"NA":689},{"trials":676,"activeCount":93},[],{"trials":678,"activeCount":93},[],{"trials":680,"activeCount":93},[],{"trials":682,"activeCount":93},[],{"trials":684,"activeCount":93},[685],{"nctId":660,"briefTitle":661,"status":283,"phases":686,"primaryCompletion":663,"completion":663,"start":664,"enrollment":665,"conditions":687,"interventions":688},[85],[667,668],[647,670],{"trials":690,"activeCount":93},[],{"intervention":692,"totalTrials":89,"cells":693},"Mecamylamine Oral",{"EARLY_PHASE1":694,"PHASE1":696,"PHASE2":698,"PHASE3":700,"PHASE4":702,"NA":715},{"trials":695,"activeCount":93},[],{"trials":697,"activeCount":93},[],{"trials":699,"activeCount":93},[],{"trials":701,"activeCount":93},[],{"trials":703,"activeCount":93},[704],{"nctId":705,"briefTitle":706,"status":707,"phases":708,"primaryCompletion":709,"completion":710,"start":711,"enrollment":30,"conditions":712,"interventions":714},"NCT03914677","Mecamylamine for Autonomic Dysreflexia Prophylaxis","UNKNOWN",[85],"2020-03-17","2020-12-31","2019-06-13",[713],"Spinal Cord Injuries",[692],{"trials":716,"activeCount":93},[],{"intervention":718,"totalTrials":89,"cells":719},"Dronabinol Cap 5 milligrams",{"EARLY_PHASE1":720,"PHASE1":722,"PHASE2":724,"PHASE3":726,"PHASE4":728,"NA":741},{"trials":721,"activeCount":93},[],{"trials":723,"activeCount":93},[],{"trials":725,"activeCount":93},[],{"trials":727,"activeCount":93},[],{"trials":729,"activeCount":93},[730],{"nctId":731,"briefTitle":732,"status":283,"phases":733,"primaryCompletion":734,"completion":734,"start":735,"enrollment":736,"conditions":737,"interventions":739},"NCT03008005","Effects of Delta-9 Tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R61 Study",[85],"2019-12-31","2017-06-01",46,[738],"PostTraumatic Stress Disorder",[718,740],"Dronabinol Cap 10 milligrams",{"trials":742,"activeCount":93},[],{"intervention":740,"totalTrials":89,"cells":744},{"EARLY_PHASE1":745,"PHASE1":747,"PHASE2":749,"PHASE3":751,"PHASE4":753,"NA":759},{"trials":746,"activeCount":93},[],{"trials":748,"activeCount":93},[],{"trials":750,"activeCount":93},[],{"trials":752,"activeCount":93},[],{"trials":754,"activeCount":93},[755],{"nctId":731,"briefTitle":732,"status":283,"phases":756,"primaryCompletion":734,"completion":734,"start":735,"enrollment":736,"conditions":757,"interventions":758},[85],[738],[718,740],{"trials":760,"activeCount":93},[],{"intervention":762,"totalTrials":89,"cells":763},"ACTH",{"EARLY_PHASE1":764,"PHASE1":766,"PHASE2":768,"PHASE3":770,"PHASE4":772,"NA":785},{"trials":765,"activeCount":93},[],{"trials":767,"activeCount":93},[],{"trials":769,"activeCount":93},[],{"trials":771,"activeCount":93},[],{"trials":773,"activeCount":93},[774],{"nctId":775,"briefTitle":776,"status":283,"phases":777,"primaryCompletion":778,"completion":779,"start":780,"enrollment":781,"conditions":782,"interventions":784},"NCT02092883","Evaluation of Neuroinflammation in Children With Infantile Spasms",[85],"2016-07","2017-07","2013-03",8,[783],"Infantile Spasms",[762],{"trials":786,"activeCount":93},[],{"intervention":788,"totalTrials":89,"cells":789},"Tekturna(Aliskiren) plus placebo",{"EARLY_PHASE1":790,"PHASE1":792,"PHASE2":794,"PHASE3":796,"PHASE4":798,"NA":810},{"trials":791,"activeCount":93},[],{"trials":793,"activeCount":93},[],{"trials":795,"activeCount":93},[],{"trials":797,"activeCount":93},[],{"trials":799,"activeCount":93},[800],{"nctId":801,"briefTitle":802,"status":707,"phases":803,"primaryCompletion":804,"completion":805,"start":806,"enrollment":807,"conditions":808,"interventions":809},"NCT01472796","Vitamin D Augmentation of Tekturna (Aliskiren) in Hypertension",[85],"2013-07","2014-03","2011-07",92,[15],[788],{"trials":811,"activeCount":93},[],{"intervention":813,"totalTrials":89,"cells":814},"Fondaparinux",{"EARLY_PHASE1":815,"PHASE1":817,"PHASE2":819,"PHASE3":821,"PHASE4":823,"NA":835},{"trials":816,"activeCount":93},[],{"trials":818,"activeCount":93},[],{"trials":820,"activeCount":93},[],{"trials":822,"activeCount":93},[],{"trials":824,"activeCount":93},[825],{"nctId":826,"briefTitle":827,"status":283,"phases":828,"primaryCompletion":829,"completion":829,"start":830,"enrollment":831,"conditions":832,"interventions":834},"NCT01467583","Fondaparinux in Critically Ill Patients With Renal Failure",[85],"2013-11","2011-11",32,[833],"Venous Thromboembolism",[813],{"trials":836,"activeCount":93},[],{"intervention":838,"totalTrials":89,"cells":839},"Rapamune and Prograf",{"EARLY_PHASE1":840,"PHASE1":842,"PHASE2":844,"PHASE3":846,"PHASE4":848,"NA":860},{"trials":841,"activeCount":93},[],{"trials":843,"activeCount":93},[],{"trials":845,"activeCount":93},[],{"trials":847,"activeCount":93},[],{"trials":849,"activeCount":93},[850],{"nctId":851,"briefTitle":852,"status":707,"phases":853,"completion":854,"start":855,"enrollment":856,"conditions":857,"interventions":859},"NCT00252655","Use of Sirolimus vs. Tacrolimus For African-American Renal Transplant Recipients",[85],"2009-06","2004-01",40,[858],"Kidney Transplantation",[838],{"trials":861,"activeCount":93},[],{"intervention":863,"totalTrials":89,"cells":864},"1.3% Liposomal Bupivacaine",{"EARLY_PHASE1":865,"PHASE1":867,"PHASE2":869,"PHASE3":871,"PHASE4":873,"NA":886},{"trials":866,"activeCount":93},[],{"trials":868,"activeCount":93},[],{"trials":870,"activeCount":93},[],{"trials":872,"activeCount":93},[],{"trials":874,"activeCount":93},[875],{"nctId":876,"briefTitle":877,"status":283,"phases":878,"primaryCompletion":879,"completion":879,"start":880,"enrollment":881,"conditions":882,"interventions":884},"NCT02472314","Exparel for Postoperative Pain Management in Shoulder Surgery",[85],"2017-05","2015-06",70,[883],"Fracture of Shoulder and Upper Arm",[863,885],"0.125% Bupivacaine",{"trials":887,"activeCount":93},[],{"intervention":885,"totalTrials":89,"cells":889},{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":894,"PHASE3":896,"PHASE4":898,"NA":904},{"trials":891,"activeCount":93},[],{"trials":893,"activeCount":93},[],{"trials":895,"activeCount":93},[],{"trials":897,"activeCount":93},[],{"trials":899,"activeCount":93},[900],{"nctId":876,"briefTitle":877,"status":283,"phases":901,"primaryCompletion":879,"completion":879,"start":880,"enrollment":881,"conditions":902,"interventions":903},[85],[883],[863,885],{"trials":905,"activeCount":93},[],{"intervention":907,"totalTrials":89,"cells":908},"Metformin",{"EARLY_PHASE1":909,"PHASE1":911,"PHASE2":913,"PHASE3":915,"PHASE4":928,"NA":930},{"trials":910,"activeCount":93},[],{"trials":912,"activeCount":93},[],{"trials":914,"activeCount":93},[],{"trials":916,"activeCount":93},[917],{"nctId":918,"briefTitle":919,"status":144,"phases":920,"primaryCompletion":921,"completion":922,"start":923,"enrollment":93,"conditions":924,"interventions":926},"NCT03452267","Insulin Signaling in Skeletal Muscle",[83,84],"2024-12","2025-06","2019-09-01",[925],"Insulin Sensitivity",[907,927],"Pioglitazone",{"trials":929,"activeCount":93},[],{"trials":931,"activeCount":93},[],{"intervention":927,"totalTrials":89,"cells":933},{"EARLY_PHASE1":934,"PHASE1":936,"PHASE2":938,"PHASE3":940,"PHASE4":946,"NA":948},{"trials":935,"activeCount":93},[],{"trials":937,"activeCount":93},[],{"trials":939,"activeCount":93},[],{"trials":941,"activeCount":93},[942],{"nctId":918,"briefTitle":919,"status":144,"phases":943,"primaryCompletion":921,"completion":922,"start":923,"enrollment":93,"conditions":944,"interventions":945},[83,84],[925],[907,927],{"trials":947,"activeCount":93},[],{"trials":949,"activeCount":93},[],{"intervention":951,"totalTrials":89,"cells":952},"Tranexamic Acid",{"EARLY_PHASE1":953,"PHASE1":955,"PHASE2":957,"PHASE3":959,"PHASE4":971,"NA":973},{"trials":954,"activeCount":93},[],{"trials":956,"activeCount":93},[],{"trials":958,"activeCount":93},[],{"trials":960,"activeCount":93},[961],{"nctId":962,"briefTitle":963,"status":144,"phases":964,"primaryCompletion":965,"completion":965,"start":966,"enrollment":93,"conditions":967,"interventions":969},"NCT03361345","Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris",[83,84],"2022-01-09","2018-11-01",[968],"Postinflammatory Hyperpigmentation",[951,970],"Vehicle",{"trials":972,"activeCount":93},[],{"trials":974,"activeCount":93},[],{"intervention":970,"totalTrials":89,"cells":976},{"EARLY_PHASE1":977,"PHASE1":979,"PHASE2":981,"PHASE3":983,"PHASE4":989,"NA":991},{"trials":978,"activeCount":93},[],{"trials":980,"activeCount":93},[],{"trials":982,"activeCount":93},[],{"trials":984,"activeCount":93},[985],{"nctId":962,"briefTitle":963,"status":144,"phases":986,"primaryCompletion":965,"completion":965,"start":966,"enrollment":93,"conditions":987,"interventions":988},[83,84],[968],[951,970],{"trials":990,"activeCount":93},[],{"trials":992,"activeCount":93},[],{"intervention":994,"totalTrials":89,"cells":995},"Memantine",{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1000,"PHASE3":1002,"PHASE4":1015,"NA":1017},{"trials":997,"activeCount":93},[],{"trials":999,"activeCount":93},[],{"trials":1001,"activeCount":93},[],{"trials":1003,"activeCount":93},[1004],{"nctId":1005,"briefTitle":1006,"status":707,"phases":1007,"primaryCompletion":1008,"completion":1009,"start":1010,"enrollment":1011,"conditions":1012,"interventions":1014},"NCT03858270","Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine",[84],"2022-04-01","2023-07-01","2019-04-01",50,[1013],"Parkinson Disease",[994],{"trials":1016,"activeCount":93},[],{"trials":1018,"activeCount":93},[],{"intervention":1020,"totalTrials":89,"cells":1021},"Ascorbic acid",{"EARLY_PHASE1":1022,"PHASE1":1024,"PHASE2":1026,"PHASE3":1028,"PHASE4":1040,"NA":1042},{"trials":1023,"activeCount":93},[],{"trials":1025,"activeCount":93},[],{"trials":1027,"activeCount":93},[],{"trials":1029,"activeCount":93},[1030],{"nctId":1031,"briefTitle":1032,"status":283,"phases":1033,"primaryCompletion":1034,"completion":1034,"start":1035,"enrollment":1036,"conditions":1037,"interventions":1039},"NCT00484510","High Dose Ascorbic Acid Treatment of CMT1A",[83,84],"2012-12","2007-04",110,[1038],"Charcot-Marie-Tooth Disease, Type Ia",[1020],{"trials":1041,"activeCount":93},[],{"trials":1043,"activeCount":93},[],{"intervention":1045,"totalTrials":89,"cells":1046},"Intravenous iron sucrose",{"EARLY_PHASE1":1047,"PHASE1":1049,"PHASE2":1051,"PHASE3":1063,"PHASE4":1065,"NA":1067},{"trials":1048,"activeCount":93},[],{"trials":1050,"activeCount":93},[],{"trials":1052,"activeCount":93},[1053],{"nctId":1054,"briefTitle":1055,"status":144,"phases":1056,"primaryCompletion":664,"completion":1057,"start":830,"enrollment":93,"conditions":1058,"interventions":1061},"NCT01438372","IV Iron Sucrose vs Oral FeSO4 in Treating IDA in Pediatric IBD",[83],"2012-03",[1059,1060],"Iron Deficiency Anemia","Inflammatory Bowel Disease",[1045,1062],"Oral ferrous sulfate",{"trials":1064,"activeCount":93},[],{"trials":1066,"activeCount":93},[],{"trials":1068,"activeCount":93},[],{"intervention":1062,"totalTrials":89,"cells":1070},{"EARLY_PHASE1":1071,"PHASE1":1073,"PHASE2":1075,"PHASE3":1081,"PHASE4":1083,"NA":1085},{"trials":1072,"activeCount":93},[],{"trials":1074,"activeCount":93},[],{"trials":1076,"activeCount":93},[1077],{"nctId":1054,"briefTitle":1055,"status":144,"phases":1078,"primaryCompletion":664,"completion":1057,"start":830,"enrollment":93,"conditions":1079,"interventions":1080},[83],[1059,1060],[1045,1062],{"trials":1082,"activeCount":93},[],{"trials":1084,"activeCount":93},[],{"trials":1086,"activeCount":93},[],{"intervention":1088,"totalTrials":89,"cells":1089},"Minocycline",{"EARLY_PHASE1":1090,"PHASE1":1092,"PHASE2":1094,"PHASE3":1106,"PHASE4":1108,"NA":1110},{"trials":1091,"activeCount":93},[],{"trials":1093,"activeCount":93},[],{"trials":1095,"activeCount":93},[1096],{"nctId":1097,"briefTitle":1098,"status":283,"phases":1099,"primaryCompletion":1100,"completion":1101,"start":1102,"enrollment":11,"conditions":1103,"interventions":1105},"NCT01058395","Safety and Feasibility of Minocycline in the Treatment of Traumatic Brain Injury (TBI)",[82,83],"2015-09","2016-01","2010-02",[1104],"Traumatic Brain Injury",[1088],{"trials":1107,"activeCount":93},[],{"trials":1109,"activeCount":93},[],{"trials":1111,"activeCount":93},[],{"intervention":1113,"totalTrials":89,"cells":1114},"Humira Then Humira plus 3 B vitamins",{"EARLY_PHASE1":1115,"PHASE1":1117,"PHASE2":1119,"PHASE3":1131,"PHASE4":1133,"NA":1135},{"trials":1116,"activeCount":93},[],{"trials":1118,"activeCount":93},[],{"trials":1120,"activeCount":93},[1121],{"nctId":1122,"briefTitle":1123,"status":450,"phases":1124,"primaryCompletion":1125,"completion":1126,"start":1127,"enrollment":781,"conditions":1128,"interventions":1130},"NCT01704599","Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis",[82,83],"2013-06","2014-05","2009-01",[1129],"Psoriasis",[1113],{"trials":1132,"activeCount":93},[],{"trials":1134,"activeCount":93},[],{"trials":1136,"activeCount":93},[],{"intervention":1138,"totalTrials":89,"cells":1139},"Suvorexant",{"EARLY_PHASE1":1140,"PHASE1":1142,"PHASE2":1144,"PHASE3":1157,"PHASE4":1159,"NA":1161},{"trials":1141,"activeCount":93},[],{"trials":1143,"activeCount":93},[],{"trials":1145,"activeCount":93},[1146],{"nctId":1147,"briefTitle":1148,"status":450,"phases":1149,"primaryCompletion":1150,"completion":1150,"start":1151,"enrollment":1152,"conditions":1153,"interventions":1155},"NCT04262193","Dual-Orexin Antagonism As a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder",[83],"2024-07-30","2021-02-01",37,[149,1154],"Sleep",[1138,1156],"Suvorexant Placebo",{"trials":1158,"activeCount":93},[],{"trials":1160,"activeCount":93},[],{"trials":1162,"activeCount":93},[],{"intervention":1156,"totalTrials":89,"cells":1164},{"EARLY_PHASE1":1165,"PHASE1":1167,"PHASE2":1169,"PHASE3":1175,"PHASE4":1177,"NA":1179},{"trials":1166,"activeCount":93},[],{"trials":1168,"activeCount":93},[],{"trials":1170,"activeCount":93},[1171],{"nctId":1147,"briefTitle":1148,"status":450,"phases":1172,"primaryCompletion":1150,"completion":1150,"start":1151,"enrollment":1152,"conditions":1173,"interventions":1174},[83],[149,1154],[1138,1156],{"trials":1176,"activeCount":93},[],{"trials":1178,"activeCount":93},[],{"trials":1180,"activeCount":93},[],{"intervention":1182,"totalTrials":89,"cells":1183},"Extended release morphine",{"EARLY_PHASE1":1184,"PHASE1":1186,"PHASE2":1188,"PHASE3":1204,"PHASE4":1206,"NA":1208},{"trials":1185,"activeCount":93},[],{"trials":1187,"activeCount":93},[],{"trials":1189,"activeCount":93},[1190],{"nctId":1191,"briefTitle":1192,"status":283,"phases":1193,"primaryCompletion":1194,"completion":1195,"start":1196,"enrollment":1197,"conditions":1198,"interventions":1199},"NCT03015246","Effects of Buprenorphine\u002FNaloxone Dose on Experimental Stress Reactivity and Opioid Abstinence",[82,83],"2020-06","2020-08","2016-12",26,[18,157],[1182,1200,1201,1202,1203],"Buprenorphine\u002FNaloxone low dose","Buprenorphine\u002FNaloxone moderate dose","Buprenorphine\u002FNaloxone high dose","Active stressor",{"trials":1205,"activeCount":93},[],{"trials":1207,"activeCount":93},[],{"trials":1209,"activeCount":93},[],{"intervention":1200,"totalTrials":89,"cells":1211},{"EARLY_PHASE1":1212,"PHASE1":1214,"PHASE2":1216,"PHASE3":1222,"PHASE4":1224,"NA":1226},{"trials":1213,"activeCount":93},[],{"trials":1215,"activeCount":93},[],{"trials":1217,"activeCount":93},[1218],{"nctId":1191,"briefTitle":1192,"status":283,"phases":1219,"primaryCompletion":1194,"completion":1195,"start":1196,"enrollment":1197,"conditions":1220,"interventions":1221},[82,83],[18,157],[1182,1200,1201,1202,1203],{"trials":1223,"activeCount":93},[],{"trials":1225,"activeCount":93},[],{"trials":1227,"activeCount":93},[],{"intervention":1201,"totalTrials":89,"cells":1229},{"EARLY_PHASE1":1230,"PHASE1":1232,"PHASE2":1234,"PHASE3":1240,"PHASE4":1242,"NA":1244},{"trials":1231,"activeCount":93},[],{"trials":1233,"activeCount":93},[],{"trials":1235,"activeCount":93},[1236],{"nctId":1191,"briefTitle":1192,"status":283,"phases":1237,"primaryCompletion":1194,"completion":1195,"start":1196,"enrollment":1197,"conditions":1238,"interventions":1239},[82,83],[18,157],[1182,1200,1201,1202,1203],{"trials":1241,"activeCount":93},[],{"trials":1243,"activeCount":93},[],{"trials":1245,"activeCount":93},[],{"intervention":1202,"totalTrials":89,"cells":1247},{"EARLY_PHASE1":1248,"PHASE1":1250,"PHASE2":1252,"PHASE3":1258,"PHASE4":1260,"NA":1262},{"trials":1249,"activeCount":93},[],{"trials":1251,"activeCount":93},[],{"trials":1253,"activeCount":93},[1254],{"nctId":1191,"briefTitle":1192,"status":283,"phases":1255,"primaryCompletion":1194,"completion":1195,"start":1196,"enrollment":1197,"conditions":1256,"interventions":1257},[82,83],[18,157],[1182,1200,1201,1202,1203],{"trials":1259,"activeCount":93},[],{"trials":1261,"activeCount":93},[],{"trials":1263,"activeCount":93},[],{"intervention":1203,"totalTrials":89,"cells":1265},{"EARLY_PHASE1":1266,"PHASE1":1268,"PHASE2":1270,"PHASE3":1276,"PHASE4":1278,"NA":1280},{"trials":1267,"activeCount":93},[],{"trials":1269,"activeCount":93},[],{"trials":1271,"activeCount":93},[1272],{"nctId":1191,"briefTitle":1192,"status":283,"phases":1273,"primaryCompletion":1194,"completion":1195,"start":1196,"enrollment":1197,"conditions":1274,"interventions":1275},[82,83],[18,157],[1182,1200,1201,1202,1203],{"trials":1277,"activeCount":93},[],{"trials":1279,"activeCount":93},[],{"trials":1281,"activeCount":93},[],{"intervention":1283,"totalTrials":89,"cells":1284},"Propranolol",{"EARLY_PHASE1":1285,"PHASE1":1287,"PHASE2":1289,"PHASE3":1300,"PHASE4":1302,"NA":1304},{"trials":1286,"activeCount":93},[],{"trials":1288,"activeCount":93},[],{"trials":1290,"activeCount":93},[1291],{"nctId":1292,"briefTitle":1293,"status":450,"phases":1294,"primaryCompletion":1295,"completion":1100,"start":1296,"enrollment":573,"conditions":1297,"interventions":1299},"NCT00611871","The Use of Propranolol to Block Memory Reconsolidation in PTSD",[83],"2015-08","2007-09",[1298],"Posttraumatic Stress Disorders",[1283],{"trials":1301,"activeCount":93},[],{"trials":1303,"activeCount":93},[],{"trials":1305,"activeCount":93},[],{"intervention":1307,"totalTrials":89,"cells":1308},"Mirtazapine",{"EARLY_PHASE1":1309,"PHASE1":1311,"PHASE2":1313,"PHASE3":1325,"PHASE4":1327,"NA":1329},{"trials":1310,"activeCount":93},[],{"trials":1312,"activeCount":93},[],{"trials":1314,"activeCount":93},[1315],{"nctId":1316,"briefTitle":1317,"status":283,"phases":1318,"primaryCompletion":1319,"completion":1319,"start":1320,"enrollment":1321,"conditions":1322,"interventions":1324},"NCT04799782","Role of Mirtazapine in Ameliorating Sleep Disordered Breathing",[83],"2019-05-18","2017-01",18,[713,1323],"Sleep Disordered Breathing",[1307],{"trials":1326,"activeCount":93},[],{"trials":1328,"activeCount":93},[],{"trials":1330,"activeCount":93},[],{"intervention":1332,"totalTrials":89,"cells":1333},"Immediate-release Oral Morphine Sulfate",{"EARLY_PHASE1":1334,"PHASE1":1336,"PHASE2":1348,"PHASE3":1350,"PHASE4":1352,"NA":1354},{"trials":1335,"activeCount":93},[],{"trials":1337,"activeCount":93},[1338],{"nctId":1339,"briefTitle":1340,"status":707,"phases":1341,"primaryCompletion":1342,"completion":1342,"start":1343,"enrollment":856,"conditions":1344,"interventions":1347},"NCT04030442","Cannabidiol, Morphine, Pain",[82],"2025-01-26","2019-05-01",[1345,1346],"CBD","Chronic Pain",[1332],{"trials":1349,"activeCount":93},[],{"trials":1351,"activeCount":93},[],{"trials":1353,"activeCount":93},[],{"trials":1355,"activeCount":93},[],{"intervention":1357,"totalTrials":89,"cells":1358},"Yohimbine Hydrochloride",{"EARLY_PHASE1":1359,"PHASE1":1361,"PHASE2":1375,"PHASE3":1377,"PHASE4":1379,"NA":1381},{"trials":1360,"activeCount":93},[],{"trials":1362,"activeCount":93},[1363],{"nctId":1364,"briefTitle":1365,"status":283,"phases":1366,"primaryCompletion":1367,"completion":1367,"start":1368,"enrollment":1369,"conditions":1370,"interventions":1372},"NCT03670212","Investigation of Nicotine Seeking Behavior in Current Smokers",[82],"2016-10-04","2016-01-07",21,[1371],"Cigarette Smoking",[1357,1373,1374],"Hydrocortisone","Lactose Monohydrate Powder",{"trials":1376,"activeCount":93},[],{"trials":1378,"activeCount":93},[],{"trials":1380,"activeCount":93},[],{"trials":1382,"activeCount":93},[],{"intervention":1373,"totalTrials":89,"cells":1384},{"EARLY_PHASE1":1385,"PHASE1":1387,"PHASE2":1393,"PHASE3":1395,"PHASE4":1397,"NA":1399},{"trials":1386,"activeCount":93},[],{"trials":1388,"activeCount":93},[1389],{"nctId":1364,"briefTitle":1365,"status":283,"phases":1390,"primaryCompletion":1367,"completion":1367,"start":1368,"enrollment":1369,"conditions":1391,"interventions":1392},[82],[1371],[1357,1373,1374],{"trials":1394,"activeCount":93},[],{"trials":1396,"activeCount":93},[],{"trials":1398,"activeCount":93},[],{"trials":1400,"activeCount":93},[],{"intervention":1374,"totalTrials":89,"cells":1402},{"EARLY_PHASE1":1403,"PHASE1":1405,"PHASE2":1411,"PHASE3":1413,"PHASE4":1415,"NA":1417},{"trials":1404,"activeCount":93},[],{"trials":1406,"activeCount":93},[1407],{"nctId":1364,"briefTitle":1365,"status":283,"phases":1408,"primaryCompletion":1367,"completion":1367,"start":1368,"enrollment":1369,"conditions":1409,"interventions":1410},[82],[1371],[1357,1373,1374],{"trials":1412,"activeCount":93},[],{"trials":1414,"activeCount":93},[],{"trials":1416,"activeCount":93},[],{"trials":1418,"activeCount":93},[],{"intervention":1420,"totalTrials":89,"cells":1421},"N-acetyl cysteine",{"EARLY_PHASE1":1422,"PHASE1":1424,"PHASE2":1434,"PHASE3":1436,"PHASE4":1438,"NA":1440},{"trials":1423,"activeCount":93},[],{"trials":1425,"activeCount":93},[1426],{"nctId":1427,"briefTitle":1428,"status":283,"phases":1429,"primaryCompletion":1430,"completion":1430,"start":1431,"enrollment":1369,"conditions":1432,"interventions":1433},"NCT03154580","Marijuana Cue-Reactivity & Seeking Behavior in Regular Cannabis Users",[82],"2023-06-27","2017-05-01",[27],[1420],{"trials":1435,"activeCount":93},[],{"trials":1437,"activeCount":93},[],{"trials":1439,"activeCount":93},[],{"trials":1441,"activeCount":93},[],{"intervention":1443,"totalTrials":89,"cells":1444},"Gardasil",{"EARLY_PHASE1":1445,"PHASE1":1447,"PHASE2":1459,"PHASE3":1461,"PHASE4":1463,"NA":1465},{"trials":1446,"activeCount":93},[],{"trials":1448,"activeCount":93},[1449],{"nctId":1450,"briefTitle":1451,"status":283,"phases":1452,"primaryCompletion":1453,"completion":1454,"start":1455,"enrollment":1152,"conditions":1456,"interventions":1458},"NCT01741012","Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients",[82],"2015-01","2015-11","2013-01",[1457],"Systemic Lupus Erythematosus",[1443],{"trials":1460,"activeCount":93},[],{"trials":1462,"activeCount":93},[],{"trials":1464,"activeCount":93},[],{"trials":1466,"activeCount":93},[],{"intervention":1468,"totalTrials":89,"cells":1469},"Yohimbine",{"EARLY_PHASE1":1470,"PHASE1":1472,"PHASE2":1482,"PHASE3":1484,"PHASE4":1486,"NA":1488},{"trials":1471,"activeCount":93},[],{"trials":1473,"activeCount":93},[1474],{"nctId":1475,"briefTitle":1476,"status":283,"phases":1477,"primaryCompletion":1478,"completion":1478,"start":1479,"enrollment":573,"conditions":1480,"interventions":1481},"NCT03154567","Effects of Stress and Drug-cue Exposure (SCM)",[82],"2023-10-27","2017-11-01",[27],[1468],{"trials":1483,"activeCount":93},[],{"trials":1485,"activeCount":93},[],{"trials":1487,"activeCount":93},[],{"trials":1489,"activeCount":93},[],{"intervention":1491,"totalTrials":89,"cells":1492},"Dronabinol 7.5 milligram oral",{"EARLY_PHASE1":1493,"PHASE1":1495,"PHASE2":1507,"PHASE3":1509,"PHASE4":1511,"NA":1513},{"trials":1494,"activeCount":93},[],{"trials":1496,"activeCount":93},[1497],{"nctId":1498,"briefTitle":1499,"status":283,"phases":1500,"primaryCompletion":1501,"completion":1501,"start":1502,"enrollment":1503,"conditions":1504,"interventions":1506},"NCT04080427","Effects of Delta9-tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R33 Study",[82],"2025-05-31","2021-04-15",102,[1505],"Posttraumatic Stress Disorder",[1491],{"trials":1508,"activeCount":93},[],{"trials":1510,"activeCount":93},[],{"trials":1512,"activeCount":93},[],{"trials":1514,"activeCount":93},[],{"intervention":1516,"totalTrials":89,"cells":1517},"Skin Care Cream",{"EARLY_PHASE1":1518,"PHASE1":1528,"PHASE2":1530,"PHASE3":1532,"PHASE4":1534,"NA":1536},{"trials":1519,"activeCount":93},[1520],{"nctId":1521,"briefTitle":1522,"status":283,"phases":1523,"primaryCompletion":1524,"completion":1524,"start":1010,"enrollment":16,"conditions":1525,"interventions":1527},"NCT03878381","Investigating the Wrinkle Reduction Potential of a Novel Compounded Skin Care Cream",[81],"2022-10-29",[1526],"Skin Care",[1516],{"trials":1529,"activeCount":93},[],{"trials":1531,"activeCount":93},[],{"trials":1533,"activeCount":93},[],{"trials":1535,"activeCount":93},[],{"trials":1537,"activeCount":93},[],{"intervention":1539,"totalTrials":89,"cells":1540},"Magic Shave Powder Gold",{"EARLY_PHASE1":1541,"PHASE1":1552,"PHASE2":1554,"PHASE3":1556,"PHASE4":1558,"NA":1560},{"trials":1542,"activeCount":93},[1543],{"nctId":1544,"briefTitle":1545,"status":144,"phases":1546,"primaryCompletion":1547,"completion":1547,"start":1548,"enrollment":93,"conditions":1549,"interventions":1551},"NCT04220502","Magic Shave Powder Gold's Affects on the Occurrence of Pseudofolliculitis Barbae",[81],"2022-05-03","2020-08-01",[1550],"Pseudofolliculitis Barbae",[1539],{"trials":1553,"activeCount":93},[],{"trials":1555,"activeCount":93},[],{"trials":1557,"activeCount":93},[],{"trials":1559,"activeCount":93},[],{"trials":1561,"activeCount":93},[],{"intervention":1563,"totalTrials":89,"cells":1564},"750 mg metronidazole\u002F 200 mg miconazole vaginal suppository",{"EARLY_PHASE1":1565,"PHASE1":1578,"PHASE2":1580,"PHASE3":1582,"PHASE4":1584,"NA":1586},{"trials":1566,"activeCount":93},[1567],{"nctId":1568,"briefTitle":1569,"status":707,"phases":1570,"primaryCompletion":1101,"completion":1571,"start":1572,"enrollment":1573,"conditions":1574,"interventions":1576},"NCT02185456","Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis",[81],"2016-03","2014-09",200,[1575],"Bacterial Vaginosis",[1563,1577],"Standard of care",{"trials":1579,"activeCount":93},[],{"trials":1581,"activeCount":93},[],{"trials":1583,"activeCount":93},[],{"trials":1585,"activeCount":93},[],{"trials":1587,"activeCount":93},[],{"intervention":1577,"totalTrials":89,"cells":1589},{"EARLY_PHASE1":1590,"PHASE1":1596,"PHASE2":1598,"PHASE3":1600,"PHASE4":1602,"NA":1604},{"trials":1591,"activeCount":93},[1592],{"nctId":1568,"briefTitle":1569,"status":707,"phases":1593,"primaryCompletion":1101,"completion":1571,"start":1572,"enrollment":1573,"conditions":1594,"interventions":1595},[81],[1575],[1563,1577],{"trials":1597,"activeCount":93},[],{"trials":1599,"activeCount":93},[],{"trials":1601,"activeCount":93},[],{"trials":1603,"activeCount":93},[],{"trials":1605,"activeCount":93},[],{"intervention":1607,"totalTrials":89,"cells":1608},"olanzapine",{"EARLY_PHASE1":1609,"PHASE1":1622,"PHASE2":1624,"PHASE3":1626,"PHASE4":1628,"NA":1630},{"trials":1610,"activeCount":93},[1611],{"nctId":1612,"briefTitle":1613,"status":283,"phases":1614,"primaryCompletion":1615,"completion":1615,"start":1616,"enrollment":1617,"conditions":1618,"interventions":1621},"NCT02708394","Molecular Mechanisms of Antipsychotic-induced Insulin Resistance",[81],"2023-10-01","2017-02-01",31,[1619,1620],"Adverse Effect of Other Antipsychotics and Neuroleptics","Insulin Resistance",[1607],{"trials":1623,"activeCount":93},[],{"trials":1625,"activeCount":93},[],{"trials":1627,"activeCount":93},[],{"trials":1629,"activeCount":93},[],{"trials":1631,"activeCount":93},[],{"intervention":1633,"totalTrials":262,"cells":1634},"Bupivacaine 0.25% Injectable Solution",{"EARLY_PHASE1":1635,"PHASE1":1637,"PHASE2":1639,"PHASE3":1641,"PHASE4":1643,"NA":1645},{"trials":1636,"activeCount":93},[],{"trials":1638,"activeCount":93},[],{"trials":1640,"activeCount":93},[],{"trials":1642,"activeCount":93},[],{"trials":1644,"activeCount":93},[],{"trials":1646,"activeCount":93},[1647,1659],{"nctId":1648,"briefTitle":1649,"status":707,"phases":1650,"primaryCompletion":1651,"completion":1651,"start":1652,"enrollment":1653,"conditions":1654,"interventions":1656},"NCT05090761","Serratus Anterior Plane Block With and Without Adjuvants in Video-assisted Thoracoscopy",[86],"2022-10","2021-10-12",120,[1655],"Post Operative Pain, Acute",[1633,1657,1658],"Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg","Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg, Buprenorphine 300 mcg",{"nctId":1660,"briefTitle":1661,"status":707,"phases":1662,"primaryCompletion":1663,"completion":1663,"start":1664,"enrollment":1573,"conditions":1665,"interventions":1667},"NCT05003765","Are Superficial Parasternal Intercostal Plane (SPIP) Blocks With Bupivacaine and With or Without Adjuvants Helpful for Post-operative Pain After Coronary Artery Bypass Grafting?",[86],"2022-05-01","2020-08-06",[1666],"Post-operative Pain Management",[1633,1668,1669],"Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg","Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg, Buprenorphine 300 mcg",{"intervention":1657,"totalTrials":89,"cells":1671},{"EARLY_PHASE1":1672,"PHASE1":1674,"PHASE2":1676,"PHASE3":1678,"PHASE4":1680,"NA":1682},{"trials":1673,"activeCount":93},[],{"trials":1675,"activeCount":93},[],{"trials":1677,"activeCount":93},[],{"trials":1679,"activeCount":93},[],{"trials":1681,"activeCount":93},[],{"trials":1683,"activeCount":93},[1684],{"nctId":1648,"briefTitle":1649,"status":707,"phases":1685,"primaryCompletion":1651,"completion":1651,"start":1652,"enrollment":1653,"conditions":1686,"interventions":1687},[86],[1655],[1633,1657,1658],{"intervention":1658,"totalTrials":89,"cells":1689},{"EARLY_PHASE1":1690,"PHASE1":1692,"PHASE2":1694,"PHASE3":1696,"PHASE4":1698,"NA":1700},{"trials":1691,"activeCount":93},[],{"trials":1693,"activeCount":93},[],{"trials":1695,"activeCount":93},[],{"trials":1697,"activeCount":93},[],{"trials":1699,"activeCount":93},[],{"trials":1701,"activeCount":93},[1702],{"nctId":1648,"briefTitle":1649,"status":707,"phases":1703,"primaryCompletion":1651,"completion":1651,"start":1652,"enrollment":1653,"conditions":1704,"interventions":1705},[86],[1655],[1633,1657,1658],{"intervention":1707,"totalTrials":89,"cells":1708},"Prednisolone",{"EARLY_PHASE1":1709,"PHASE1":1711,"PHASE2":1713,"PHASE3":1715,"PHASE4":1717,"NA":1719},{"trials":1710,"activeCount":93},[],{"trials":1712,"activeCount":93},[],{"trials":1714,"activeCount":93},[],{"trials":1716,"activeCount":93},[],{"trials":1718,"activeCount":93},[],{"trials":1720,"activeCount":93},[1721],{"nctId":1722,"briefTitle":1723,"status":707,"phases":1724,"primaryCompletion":1725,"completion":1725,"start":1726,"enrollment":1573,"conditions":1727,"interventions":1729},"NCT03352115","Postoperative Oral Corticosteroids Following Tonsillectomy",[86],"2019-01","2018-01",[1728],"Tonsillectomy",[1707,1730],"Placebos",{"intervention":1730,"totalTrials":89,"cells":1732},{"EARLY_PHASE1":1733,"PHASE1":1735,"PHASE2":1737,"PHASE3":1739,"PHASE4":1741,"NA":1743},{"trials":1734,"activeCount":93},[],{"trials":1736,"activeCount":93},[],{"trials":1738,"activeCount":93},[],{"trials":1740,"activeCount":93},[],{"trials":1742,"activeCount":93},[],{"trials":1744,"activeCount":93},[1745],{"nctId":1722,"briefTitle":1723,"status":707,"phases":1746,"primaryCompletion":1725,"completion":1725,"start":1726,"enrollment":1573,"conditions":1747,"interventions":1748},[86],[1728],[1707,1730],{"intervention":1750,"totalTrials":89,"cells":1751},"Bupropion",{"EARLY_PHASE1":1752,"PHASE1":1754,"PHASE2":1756,"PHASE3":1758,"PHASE4":1760,"NA":1762},{"trials":1753,"activeCount":93},[],{"trials":1755,"activeCount":93},[],{"trials":1757,"activeCount":93},[],{"trials":1759,"activeCount":93},[],{"trials":1761,"activeCount":93},[],{"trials":1763,"activeCount":93},[1764],{"nctId":1765,"briefTitle":1766,"status":707,"phases":1767,"primaryCompletion":1768,"completion":1768,"start":502,"enrollment":1769,"conditions":1770,"interventions":1774},"NCT01965405","Smoking Cessation for People Living With HIV\u002FAIDS",[86],"2021-12",165,[1771,1772,1773],"HIV","AIDS","Nicotine Dependence",[1750],{"intervention":1776,"totalTrials":89,"cells":1777},"Hydromorphone",{"EARLY_PHASE1":1778,"PHASE1":1780,"PHASE2":1782,"PHASE3":1784,"PHASE4":1786,"NA":1788},{"trials":1779,"activeCount":93},[],{"trials":1781,"activeCount":93},[],{"trials":1783,"activeCount":93},[],{"trials":1785,"activeCount":93},[],{"trials":1787,"activeCount":93},[],{"trials":1789,"activeCount":93},[1790],{"nctId":1791,"briefTitle":1792,"status":283,"phases":1793,"start":1794,"enrollment":1795,"conditions":1796,"interventions":1797},"NCT00218361","Effects of Post-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals",[],"2005-08",16,[18,25],[1776],{"intervention":1799,"totalTrials":89,"cells":1800},"Pharmaceutical Therapy",{"EARLY_PHASE1":1801,"PHASE1":1803,"PHASE2":1805,"PHASE3":1807,"PHASE4":1809,"NA":1811},{"trials":1802,"activeCount":93},[],{"trials":1804,"activeCount":93},[],{"trials":1806,"activeCount":93},[],{"trials":1808,"activeCount":93},[],{"trials":1810,"activeCount":93},[],{"trials":1812,"activeCount":93},[1813],{"nctId":1814,"briefTitle":1815,"status":283,"phases":1816,"primaryCompletion":1817,"completion":1818,"start":1819,"enrollment":1820,"conditions":1821,"interventions":1826},"NCT00689819","Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients",[86],"2011-05","2011-06","2008-10",123,[15,1822,1823,1824,1825],"High Blood Pressure","Ventricular Hypertrophy","Diastolic Dysfunction","Systolic Dysfunction",[1799,1799],{"intervention":1828,"totalTrials":89,"cells":1829},"Adding Magnesium as an adjuvant to the adductor canal Block (ACB) for same-day discharge total knee arthroplasty",{"EARLY_PHASE1":1830,"PHASE1":1832,"PHASE2":1834,"PHASE3":1836,"PHASE4":1838,"NA":1840},{"trials":1831,"activeCount":93},[],{"trials":1833,"activeCount":93},[],{"trials":1835,"activeCount":93},[],{"trials":1837,"activeCount":93},[],{"trials":1839,"activeCount":93},[],{"trials":1841,"activeCount":93},[1842],{"nctId":1843,"briefTitle":1844,"status":283,"phases":1845,"primaryCompletion":1846,"completion":1846,"start":1847,"enrollment":1848,"conditions":1849,"interventions":1851},"NCT05004636","Adductor Canal Blocks With Bupivacaine and Magnesium After Same-day Discharge Total Knee Arthroplasty Improve Post-operative Pain Relief and Decrease Opioid Consumption: a Prospective Randomized Controlled Trial",[86],"2021-05-29","2020-08-05",119,[1850],"Post-operative Pain, Acute",[1828],{"intervention":1853,"totalTrials":89,"cells":1854},"Adding Magnesium as an adjuvant to Bupivacaine in the adductor canal block (ACB) for same-day discharge total knee arthroplasty",{"EARLY_PHASE1":1855,"PHASE1":1857,"PHASE2":1859,"PHASE3":1861,"PHASE4":1863,"NA":1865},{"trials":1856,"activeCount":93},[],{"trials":1858,"activeCount":93},[],{"trials":1860,"activeCount":93},[],{"trials":1862,"activeCount":93},[],{"trials":1864,"activeCount":93},[],{"trials":1866,"activeCount":93},[1867],{"nctId":1868,"briefTitle":1869,"status":707,"phases":1870,"primaryCompletion":1871,"completion":1871,"start":1652,"enrollment":387,"conditions":1872,"interventions":1874},"NCT05091138","Are Adductor Canal Blocks With Bupivacaine and Added Magnesium Better at Managing Post-operative Pain Than Bupivacaine and Added Buprenorphine in Patients Undergoing Same-day Discharge Total Knee Arthroplasty?",[86],"2022-10-01",[1850,1873],"Opioid Use",[1853,1875],"Adding Buprenorphine as an adjuvant to Bupivacaine in the adductor canal block (ACB) for same-day discharge total knee arthroplasty",{"intervention":1875,"totalTrials":89,"cells":1877},{"EARLY_PHASE1":1878,"PHASE1":1880,"PHASE2":1882,"PHASE3":1884,"PHASE4":1886,"NA":1888},{"trials":1879,"activeCount":93},[],{"trials":1881,"activeCount":93},[],{"trials":1883,"activeCount":93},[],{"trials":1885,"activeCount":93},[],{"trials":1887,"activeCount":93},[],{"trials":1889,"activeCount":93},[1890],{"nctId":1868,"briefTitle":1869,"status":707,"phases":1891,"primaryCompletion":1871,"completion":1871,"start":1652,"enrollment":387,"conditions":1892,"interventions":1893},[86],[1850,1873],[1853,1875],{"intervention":1895,"totalTrials":89,"cells":1896},"Caffeine",{"EARLY_PHASE1":1897,"PHASE1":1899,"PHASE2":1901,"PHASE3":1903,"PHASE4":1905,"NA":1907},{"trials":1898,"activeCount":93},[],{"trials":1900,"activeCount":93},[],{"trials":1902,"activeCount":93},[],{"trials":1904,"activeCount":93},[],{"trials":1906,"activeCount":93},[],{"trials":1908,"activeCount":93},[1909],{"nctId":1910,"briefTitle":1911,"status":450,"phases":1912,"primaryCompletion":1913,"completion":1913,"start":1100,"enrollment":1036,"conditions":1914,"interventions":1917},"NCT02524249","Early Versus Late Caffeine for ELBW Newborns",[86],"2019-06",[1915,1916],"Bronchopulmonary Dysplasia","Apnea of Prematurity",[1895],{"intervention":1919,"totalTrials":89,"cells":1920},"THC (delta-9 tetrahydrocannabinol), d-amphetamine, oral THC",{"EARLY_PHASE1":1921,"PHASE1":1923,"PHASE2":1925,"PHASE3":1927,"PHASE4":1929,"NA":1931},{"trials":1922,"activeCount":93},[],{"trials":1924,"activeCount":93},[],{"trials":1926,"activeCount":93},[],{"trials":1928,"activeCount":93},[],{"trials":1930,"activeCount":93},[],{"trials":1932,"activeCount":93},[1933],{"nctId":1934,"briefTitle":1935,"status":283,"phases":1936,"primaryCompletion":1034,"completion":1937,"start":1938,"enrollment":1939,"conditions":1940,"interventions":1941},"NCT00943930","Marijuana Drug Discrimination and Self-Administration",[],"2014-12","2009-04",29,[27],[1919],{"intervention":1943,"totalTrials":89,"cells":1944},"Dexmedetomidine Injectable Solution",{"EARLY_PHASE1":1945,"PHASE1":1947,"PHASE2":1949,"PHASE3":1951,"PHASE4":1953,"NA":1955},{"trials":1946,"activeCount":93},[],{"trials":1948,"activeCount":93},[],{"trials":1950,"activeCount":93},[],{"trials":1952,"activeCount":93},[],{"trials":1954,"activeCount":93},[],{"trials":1956,"activeCount":93},[1957],{"nctId":1958,"briefTitle":1959,"status":707,"phases":1960,"primaryCompletion":1961,"completion":1962,"start":1963,"enrollment":387,"conditions":1964,"interventions":1966},"NCT05534230","Dexmedetomidine for Pain Reduction in CABG",[86],"2023-07-10","2024-05-09","2022-09-06",[1965],"Analgesia",[1943,1967],"Saline",{"intervention":1967,"totalTrials":89,"cells":1969},{"EARLY_PHASE1":1970,"PHASE1":1972,"PHASE2":1974,"PHASE3":1976,"PHASE4":1978,"NA":1980},{"trials":1971,"activeCount":93},[],{"trials":1973,"activeCount":93},[],{"trials":1975,"activeCount":93},[],{"trials":1977,"activeCount":93},[],{"trials":1979,"activeCount":93},[],{"trials":1981,"activeCount":93},[1982],{"nctId":1958,"briefTitle":1959,"status":707,"phases":1983,"primaryCompletion":1961,"completion":1962,"start":1963,"enrollment":387,"conditions":1984,"interventions":1985},[86],[1965],[1943,1967],{"intervention":1668,"totalTrials":89,"cells":1987},{"EARLY_PHASE1":1988,"PHASE1":1990,"PHASE2":1992,"PHASE3":1994,"PHASE4":1996,"NA":1998},{"trials":1989,"activeCount":93},[],{"trials":1991,"activeCount":93},[],{"trials":1993,"activeCount":93},[],{"trials":1995,"activeCount":93},[],{"trials":1997,"activeCount":93},[],{"trials":1999,"activeCount":93},[2000],{"nctId":1660,"briefTitle":1661,"status":707,"phases":2001,"primaryCompletion":1663,"completion":1663,"start":1664,"enrollment":1573,"conditions":2002,"interventions":2003},[86],[1666],[1633,1668,1669],{"intervention":1669,"totalTrials":89,"cells":2005},{"EARLY_PHASE1":2006,"PHASE1":2008,"PHASE2":2010,"PHASE3":2012,"PHASE4":2014,"NA":2016},{"trials":2007,"activeCount":93},[],{"trials":2009,"activeCount":93},[],{"trials":2011,"activeCount":93},[],{"trials":2013,"activeCount":93},[],{"trials":2015,"activeCount":93},[],{"trials":2017,"activeCount":93},[2018],{"nctId":1660,"briefTitle":1661,"status":707,"phases":2019,"primaryCompletion":1663,"completion":1663,"start":1664,"enrollment":1573,"conditions":2020,"interventions":2021},[86],[1666],[1633,1668,1669],{"intervention":2023,"totalTrials":89,"cells":2024},"Mepivacaine",{"EARLY_PHASE1":2025,"PHASE1":2027,"PHASE2":2029,"PHASE3":2031,"PHASE4":2033,"NA":2035},{"trials":2026,"activeCount":93},[],{"trials":2028,"activeCount":93},[],{"trials":2030,"activeCount":93},[],{"trials":2032,"activeCount":93},[],{"trials":2034,"activeCount":93},[],{"trials":2036,"activeCount":93},[2037],{"nctId":2038,"briefTitle":2039,"status":283,"phases":2040,"primaryCompletion":2041,"completion":2042,"start":2043,"enrollment":2044,"conditions":2045,"interventions":2049},"NCT01485653","Dosage of Mepivacaine in Ultrasound Axillary Block",[86],"2010-08","2010-09","2010-04",64,[2046,2047,2048],"Nerve Block","Neuromuscular Blockade","Anesthesia",[2023],{"intervention":2051,"totalTrials":89,"cells":2052},"Dronabinol",{"EARLY_PHASE1":2053,"PHASE1":2055,"PHASE2":2057,"PHASE3":2059,"PHASE4":2061,"NA":2063},{"trials":2054,"activeCount":93},[],{"trials":2056,"activeCount":93},[],{"trials":2058,"activeCount":93},[],{"trials":2060,"activeCount":93},[],{"trials":2062,"activeCount":93},[],{"trials":2064,"activeCount":93},[2065],{"nctId":2066,"briefTitle":2067,"status":283,"phases":2068,"primaryCompletion":2069,"completion":2069,"start":2070,"enrollment":2071,"conditions":2072,"interventions":2074},"NCT02069366","Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder",[86],"2019-12","2014-11",86,[2073],"Post-Traumatic Stress Disorder",[2051],{"intervention":2076,"totalTrials":89,"cells":2077},"Arixtra (fondaparinux), 2.5 mg\u002Fday-what is bioavailability",{"EARLY_PHASE1":2078,"PHASE1":2080,"PHASE2":2082,"PHASE3":2084,"PHASE4":2086,"NA":2088},{"trials":2079,"activeCount":93},[],{"trials":2081,"activeCount":93},[],{"trials":2083,"activeCount":93},[],{"trials":2085,"activeCount":93},[],{"trials":2087,"activeCount":93},[],{"trials":2089,"activeCount":93},[2090],{"nctId":2091,"briefTitle":2092,"status":707,"phases":2093,"completion":2094,"start":2095,"enrollment":856,"conditions":2096,"interventions":2098},"NCT00424281","Effectiveness of Blood Clot Medication With Concomitant Blood Pressure Medication",[],"2010-01","2007-02",[2097],"ICU Patients 18 Years or Older.",[2076]]